Personal profile

Chinese Name


Research Interests

Chinese Medicine, Clinical Pharmacology and Arthritis and related new drug discovery


Professor Lyu Aiping is Chair Professor & Dean of School of Chinese Medicine, Hong Kong Baptist University, Director of Shum Yiu Foon Shum Bik Chuen Memorial Centre for Cancer & Inflammation Research (CCIR) of HKBU, member of Academia Europaea, Chair Professor in China Academy of Chinese Medical Sciences (CACMS) and Recipient of the Distinguished Young Scholar in National Science Foundation of China (NSFC) in 2007. Prof. Lyu is also the member of Hong Kong Chinese Medicine Development Committee, the member of Hong Kong Chinese Medicine Administration Committee, the member of Biology and Medicine Panel in Hong Kong Research Grant Committee (RGC).

He obtained his bachelor degree from Jiangxi University of Traditional Chinese Medicine in 1983, and further obtained his master's and Ph.D. degrees from China Academy of Traditional Chinese Medicine (now called the China Academy of Chinese Medical Sciences, CACMS). From 2006 to 2012, he was the Director of Institute of Basic Research in Clinical Medicine, and the Director of Institute of Basic Theory of CACMS from 1999 to 2002. In 2002-2006, Prof Lyu was appointed as General Director, Jiangxi Herbfine Hi-tech Co. Ltd (National Pharmaceutical Engineering Centre), one of four centres in China in the field of Traditional Chinese Medicine industry.

His research interests mainly focus on the translational research in Chinese medicine, including pharmacological and clinical evaluation on rheumatoid arthritis with re-classification and interventions, and development of new drugs based on Chinese medicines. Also he is actively involving the research on the standardization of Chinese medicine and strategic plan research for Chinese medicine development in China.

Professor Lyu is a world-leading scientist in aptamer-based translational medicine and drug discovery.  He is not only working on basic research that demonstrates novel precision medicine-based therapeutic strategies for rheumatic disease treatment, but also on translational research in collaboration with pharmaceutical industry for the development of novel therapeutic agents. He is the director of the first aptamer R&D platform in Guangdong-Hong Kong-Macao Greater Bay Area of China, which has attracted aptamer pharmaceutical industries to establish "Aptamer Drug Valley" in the Hong Kong Science Park. He has developed the world's first ever osteoblast-targeting nucleic acid aptamer. His first discovery of the therapeutic aptamer targeting Sclerostin loop3 has been granted Orphan Drug Designation by US FDA (DRU-2019-6966) for evaluating the therapeutic potential for promoting bone formation in osteogenesis imperfect. He has also developed the first aptamer-Paclitaxel conjugates, which showcased a precision medicine-based personalized Paclitaxel for targeting specific cancer types, which is currently being developed into anti-cancer therapeutics by a pharmaceutical company.

Professor Lyu initiated the idea of using systems biology approach to identify metabolite biomarkers for subtyping RA patients with distinct clinical manifestations. His clinical research has also underpinned the potent efficacy of Tripterygium wilfordii Hook F. based therapy for RA treatment, which is recommended by the Chinese Association of Integrative Medicine as the Evidence-based Clinical Practice Guidelines. Besides, Professor Lyu has established the China's largest biobank of rheumatic diseases in Shanghai Guanghua Hospital of Integrative Medicine. The biobank has facilitated his discovery of the molecular mechanism addressing the limited efficacy of Leflunomide on bone erosion in a subgroup of RA patients with elevated serum C-reactive protein.

Prof Lyu has more than 600 publications with Google Scholar H index 66, i10-index 370 and a total of over 18000 citations. Over the years, he obtained more than 60 patents from his research activities.

Being a renowned expert and academic in the field, Prof Lyu has been appointed as Head & Spokesperson of the China Delegation, International Organization for Standardization Technical Committee on TCM (ISO/TC249) since 2009.  Besides, he also currently serves as Member of Medical Advisory Committee of National Natural Science Foundation of China (NSFC), Member of Chinese Pharmacopoeia Commission and Vice-Chairman, Terminology of Traditional Chinese Medicine Sub-Committee, China National Committee for Terms in Sciences and Technologies (CNCTST). Also he is the director of Chinese Medicine Standardization Office in State Administration of Traditional Chinese Medicine (SATCM), and the director of Chinese Medicine Standard Research Center in CACMS. Most recently, he has been elected Foreign Member of the Academia Europaea.

He was invited to serve as Visiting Scholar in a number of institutions including Lund University in Sweden, Ohio State University in the United States, Hong Kong Polytechnic University and Hong Kong University of Science and Technology. Based on his outstanding research achievement, Prof Lyu was invited as guest speakers in various international academic conferences.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being
  • SDG 4 - Quality Education
  • SDG 6 - Clean Water and Sanitation
  • SDG 9 - Industry, Innovation, and Infrastructure
  • SDG 12 - Responsible Consumption and Production
  • SDG 17 - Partnerships for the Goals


Dive into the research topics where Aiping LYU is active. Topic labels come from the works of this scholar.
  • 1 Similar Scholars

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or